Sanofi Settles 4,000 Zantac Cancer Lawsuits, But Questions Remain

French pharmaceutical giant Sanofi has agreed to settle a significant chunk of lawsuits alleging its now discontinued heartburn drug Zantac caused cancer. The move resolves roughly 4,000 personal injury claims in various U.S. state courts, but thousands more remain outstanding, particularly in Delaware.

Speak to a Zantac Lawyer and get a FREE case review Today!

Settlement details and Sanofi's stance

Sanofi has chosen not to reveal the details of the settlements related to its heartburn medication, Zantac, stating that this decision does not imply an acknowledgment of any wrongdoing. The company has expressed that settling is a strategic choice to bypass the continuous expenses and disruptions associated with lengthy court proceedings. This stance is consistent with their reaction to a 2022 federal court ruling in Florida, which dismissed similar lawsuits for lacking substantial scientific proof that Zantac is linked to cancer.

While Sanofi settles these 4,000 claims, a much larger pool of lawsuits – over 20,000 – awaits them in Delaware state court. Here, a judge is deliberating on whether scientific evidence supports the plaintiffs' claims in what amounts to around 70,000 cases against Sanofi and others, including pharmaceutical giants GSK, Pfizer, and Boehringer Ingelheim. 

The plaintiffs' attorneys are confident in their pursuit against Sanofi and other drugmakers and are actively preparing for upcoming trials in California. Highlighting this resolve, as reported by Reuters, lead plaintiffs’ attorneys Jennifer Moore and Brent Wisner shared their satisfaction with Sanofi's decision to settle some of the claims. They emphasized their commitment to advancing the litigation against other involved drugmakers. 

"We are pushing forward aggressively against GSK and Boehringer Ingelheim and are preparing for multiple trials in California state court this year," stated Moore.

Zantac's history and the NDMA controversy

Zantac, once a pharmaceutical success story, made its market debut in the 1980s and rapidly climbed to fame as one of the first drugs to achieve over $1 billion in annual sales. Initially developed by Glaxo, which is now incorporated into GSK, the medication went through several ownerships before coming under Sanofi's wing.

However, the reputation of Zantac took a hit in 2019 when investigations revealed the presence of NDMA, a potential carcinogen, in certain Zantac tablets. Scientific tests showed that ranitidine, the active ingredient in Zantac, could transform into NDMA either over time or when exposed to heat. This discovery led to numerous legal claims from individuals who contracted cancer, allegedly due to Zantac use, arguing that the pharmaceutical companies were aware—or should have been aware—of the cancer risks and neglected to inform the public.

In response to the NDMA findings, the FDA called for Zantac to be withdrawn from the market in 2020, prompting Sanofi to introduce Zantac360, a new version of the medication formulated with a different active ingredient to address safety concerns.

Sanofi's settlement of 4,000 lawsuits marks progress in addressing Zantac's legal troubles. However, with more cases pending in Delaware and California, the final effects on Sanofi and other drugmakers are still undecided. 

Speak to a Zantac Lawyer and get a FREE case review Today!